A5060586728- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Medical Imaging and Pathology Studies
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Radioactive Decay and Measurement Techniques
- Mass Spectrometry Techniques and Applications
- Bone health and treatments
- Boron Compounds in Chemistry
- Orthopaedic implants and arthroplasty
- Endometrial and Cervical Cancer Treatments
- Cancer-related gene regulation
- Nanoplatforms for cancer theranostics
- Cardiac Structural Anomalies and Repair
- Prostate Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Radioactive element chemistry and processing
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Neuroblastoma Research and Treatments
- Endometriosis Research and Treatment
Klinik und Poliklinik für Nuklearmedizin
2018-2025
University Hospital Magdeburg
2021-2024
Otto-von-Guericke University Magdeburg
2022-2024
Positron (United States)
2020-2021
Sickle Cell Institute Chhattisgarh, Raipur
2020
University Hospital Bonn
2015-2019
Johannes Gutenberg University Mainz
2012-2018
University Medical Center
2018
Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted of metastatic prostate cancer. We analysed retrospectively the early side effects and response rate in first patients, who received Lu-PSMA our departments.RLT was performed ten hormone- and/or chemo-refractory patients distant metastases progressive disease (mean age 73.5 years). (68)Ga-PSMA HBED-CC PET/CT all prior to RLT. The median PSA level 298.5 ng/ml (range 5-853...
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) a targeted metastatic In this study, we retrospectively analyzed side effects response rate 24 hormone and/or chemorefractory PC patients mean age 75.2 years (range: 64-82) distant metastases progressive disease according to PSA level,...
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true theranostic concept for diagnosis and therapy in patients with relapsed or metastatic prostate cancer. The aim of this study was to evaluate the response tolerability single dose <sup>177</sup>Lu-PSMA-617 large cohort castration-resistant cancer (mCRPC). <b>Methods:</b> data 82 consecutive (median age, 73 y; range, 43–87 y) mCRPC who received (mean, 5.9 ± 0.5 GBq) were retrospectively analyzed. Data collected at...
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) a novel targeted for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on therapeutic response measured by antigen (PSA) 2 mo after RLT.RLT was performed in 40 hormone-refractory patients distant metastases and progressive disease (mean age, 71.4 y). 68Ga-PSMA-11 PET/CT all 1-2 wk before RLT. All were treated mean 6 GBq. The SUVmax tumor lesions...
Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) prostate cancer as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life this positron emitter precludes prolonged acquisition periods, required pre-therapeutic dosimetry or...
Fibroblast activation protein (FAP) is a proline selective serine protease that overexpressed in tumor stroma and lesions of many other diseases are characterized by tissue remodeling. In 2014, most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity high selectivity toward related enzymes such prolyl oligopeptidase (PREP) the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 DPP2 were developed. This inhibitor has been adopted recently groups create radiopharmaceuticals...
// Florian C. Gaertner 1, * , Khalil Halabi Hojjat Ahmadzadehfar 1 Stefan Kürpig Elisabeth Eppard Charalambos Kotsikopoulos Nikolaos Liakos Ralph A. Bundschuh Holger Strunk 2 and Markus Essler Department of Nuclear Medicine, University Hospital Bonn, Germany Radiology, These authors contributed equally to this work Correspondence to: Gaertner, email: florian.gaertner@ukbonn.de Keywords: PSMA, PET/CT, radionuclide therapy, prostate cancer, tumor load Received: November 10, 2016 Accepted: June...
Radioligand therapy with 177Lu-PSMA-617 is an innovative and effective for castrate-resistant metastatic prostate cancer patients. For patients symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide 223Ra-dichloride as a single therapeutic agent or in combination hormone therapy. The aim of this study was to evaluate safety repeated cycles after exposure more 223Ra. Forty-nine were treated three Lu-PSMA-617 divided into two groups subjected history...
Abstract Introduction PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands albumin-binding entity was demonstrated a promising measure to increase tumor uptake in preclinical experiments. The aim this study translate clinical setting and evaluate safety dosimetry [ 177 Lu]Lu-PSMA-ALB-56, novel radioligand properties. Methods Ten...
Post-processing by means of a cation-exchanger-based protocol is an efficient strategy for purification and concentration generator-derived (68)Ga. It ensures the removal (68)Ge before (68)Ga-radiopharmaceutical preparation high labeling yields (68)Ga-labeled radiopharmaceuticals routine medical application.In effort to overcome problem associated with acetone in currently applied method, we have investigated feasibility replacing it ethanol. The (68)Ga from coeluted metallic impurities...
Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for <sup>177</sup>Lu-DOTA-zoledronic acid (<sup>177</sup>Lu-DOTA-ZOL). In this study, the safety dosimetry single dose <sup>177</sup>Lu-DOTA-ZOL were evaluated on basis series SPECT/CT images blood samples. <b>Methods:</b> Nine patients with exclusive metastases from metastatic castration-resistant prostate cancer (mCRPC)...
Aim In vivo pharmacokinetic analysis of [ 44 Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity 177 Lu]Lu-PSMA-617 and predict maximum permissible for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics evaluated in 5 carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions blood sample collection over 19.5 hours, as well urine at 2 time points. Total measured source organs PET...
Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields defined by temperature, period of labeling, amount precursor, pH etc. As recently observed, radiolabeling (RCY) seem to increase the presence non-aqueous solvents. Consequently, this effect was investigated systematically using as solvent (n-as), which is widely utilized medicine, and DOTATOC model compound.To determine impact on efficacy, "standard" labeling...
Preclinical biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy bone metastases. We evaluated normal organ absorbed doses resulting from therapeutic in patients with metastatic skeletal disease.Four disease (age range, 64-83 years) secondary to castration-resistant prostate carcinoma or bronchial were treated mean dose 5968 ± 64 MBq (161.3 mCi) [177Lu]Lu-DOTAZOL. Biodistribution was assessed...
The importance of personalized medicine is growing, since there an urged need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach established tool for a specific molecular targeting in means diagnostics therapy. visualisation potential targets can help predict if patient would benefit from particular treatment or not. Thanks quick development radiopharmaceuticals diagnostic techniques, use agents constantly rising. this article important milestones...